Latest Period
Q1 2026
Security Snapshot
Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD) Institutional Ownership
CUSIP: 002942100
13F Institutional Holders and Ownership History from Q1 2025 to Q1 2026
Institutions Reporting
77
Shares (Excl. Options)
10,199,105
Price
$3.77
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.00001 per share (the "Shares")
- Symbol
- AARD on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 10,199,105
- Total 13F value
- $38,449,918
- Portfolio coverage rank
- 0%
- Share change
- -536,003
- Value change
- -$10,262,158
- Number of holders
- 77
- Shares outstanding
- 21,303,054
- SEC-reported price per share
- $6.11
- Insider filing price
- $6.11
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- AARD - Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") is tracked under CUSIP 002942100.
- 77 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 65 to 77 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $141,005,712 to $38,449,918.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 77 institutions filings for Q1 2026.
Security key
002942100
Latest holder period
Q1 2026
13F holders
77
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
AARD full holder history
Aardvark Therapeutics, Inc. SEC filings
Aardvark Therapeutics, Inc. company facts
Aardvark Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 002942100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
AARD
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Lee Tien-Li | 14% | $34,103,965 | 2,983,724 | Tien-Li Lee | 31 Mar 2025 | |||
| Tan Finian | 9.6% | $23,441,810 | 2,050,902 | Vickers Venture Fund VI Pte. Ltd. | 12 Feb 2025 | |||
| CITADEL ADVISORS LLC | 5.6% | $13,635,659 | 1,192,971 | Kenneth Griffin | 14 Feb 2025 |
As of 31 Mar 2026, 77 institutional investors reported holding 10,199,105 shares of Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD). This represents 48% of the company’s total 21,303,054 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
46%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Decheng Capital LLC | 18% | 3,917,299 | 0% | 2.2% | $14,768,217 |
| CITADEL ADVISORS LLC | 5.8% | 1,242,777 | -3.6% | 0% | $4,685,269 |
| Laurion Capital Management LP | 4.9% | 1,034,459 | +1.9% | 0.37% | $3,899,910 |
| BlackRock, Inc. | 3.7% | 792,571 | +1% | 0% | $2,987,992 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.6% | 554,101 | 0% | 0% | $2,088,961 |
| Tetragon Partners GP Ltd | 1.5% | 316,621 | 0.23% | $1,193,661 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 309,449 | +3.9% | 0% | $1,166,884 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.4% | 300,000 | 0% | $1,131,000 | |
| STATE STREET CORP | 0.94% | 199,322 | +26% | 0% | $751,444 |
| TWO SIGMA INVESTMENTS, LP | 0.77% | 163,355 | +27% | 0% | $615,848 |
| UBS Group AG | 0.74% | 157,888 | +488% | 0% | $595,238 |
| AQR CAPITAL MANAGEMENT LLC | 0.63% | 134,495 | 0% | $507,046 | |
| MILLENNIUM MANAGEMENT LLC | 0.46% | 98,334 | -80% | 0% | $370,719 |
| NORTHERN TRUST CORP | 0.42% | 88,599 | -0.78% | 0% | $334,019 |
| VANGUARD FIDUCIARY TRUST CO | 0.39% | 83,210 | 0% | 0% | $313,702 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.35% | 75,149 | 0% | 0% | $283,312 |
| Woodline Partners LP | 0.34% | 72,429 | 0% | $273,057 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.33% | 70,792 | 0% | $266,886 | |
| CANTOR FITZGERALD, L. P. | 0.31% | 66,682 | -27% | 0.01% | $251,391 |
| CITIGROUP INC | 0.22% | 46,265 | +5064% | 0% | $174,419 |
| Cresset Asset Management, LLC | 0.2% | 43,259 | 0% | $163,086 | |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.16% | 33,684 | -89% | 0.01% | $126,989 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.14% | 30,637 | 0.01% | $115,501 | |
| Bank of New York Mellon Corp | 0.14% | 29,320 | +31% | 0% | $110,536 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.13% | 28,000 | -11% | 0% | $105,560 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Latest
Q1 2026
Rows shown
1-5 of 5
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 10,199,105 | $38,449,918 | -$10,262,158 | $3.77 | 77 |
| 2025 Q4 | 10,747,406 | $141,005,712 | +$11,023,600 | $13.12 | 65 |
| 2025 Q3 | 9,460,972 | $125,736,962 | +$6,781,972 | $13.29 | 48 |
| 2025 Q2 | 8,915,770 | $120,541,916 | +$8,913,830 | $13.52 | 35 |
| 2025 Q1 | 8,686,452 | $65,110,057 | +$64,849,535 | $7.51 | 27 |